- Home
- CCAP vs TERN Comparison
CCAP vs TERN Comparison
Compare CCAP & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCAP
- TERN
- Stock Information
- Founded
- CCAP 2015
- TERN 2017
- Country
- CCAP United States
- TERN United States
- Employees
- CCAP N/A
- TERN N/A
- Industry
- CCAP Finance: Consumer Services
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- CCAP Finance
- TERN Health Care
- Exchange
- CCAP Nasdaq
- TERN Nasdaq
- Market Cap
- CCAP 695.6M
- TERN 586.0M
- IPO Year
- CCAP N/A
- TERN 2021
- Fundamental
- Price
- CCAP $19.06
- TERN $5.71
- Analyst Decision
- CCAP Buy
- TERN Buy
- Analyst Count
- CCAP 6
- TERN 6
- Target Price
- CCAP $19.00
- TERN $16.42
- AVG Volume (30 Days)
- CCAP 113.2K
- TERN 1.3M
- Earning Date
- CCAP 11-12-2024
- TERN 11-12-2024
- Dividend Yield
- CCAP 10.67%
- TERN N/A
- EPS Growth
- CCAP 54.68
- TERN N/A
- EPS
- CCAP 2.55
- TERN N/A
- Revenue
- CCAP $200,903,000.00
- TERN N/A
- Revenue This Year
- CCAP $8.28
- TERN N/A
- Revenue Next Year
- CCAP N/A
- TERN N/A
- P/E Ratio
- CCAP $7.50
- TERN N/A
- Revenue Growth
- CCAP 19.05
- TERN N/A
- 52 Week Low
- CCAP $15.91
- TERN $3.59
- 52 Week High
- CCAP $19.63
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- CCAP 62.59
- TERN 31.42
- Support Level
- CCAP $18.12
- TERN $5.57
- Resistance Level
- CCAP $19.20
- TERN $7.53
- Average True Range (ATR)
- CCAP 0.29
- TERN 0.46
- MACD
- CCAP 0.09
- TERN -0.11
- Stochastic Oscillator
- CCAP 92.00
- TERN 11.52
About CCAP Crescent Capital BDC Inc. Common stock
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.